Among patients with advanced and/or metastatic hormone receptor–positive HER-2 negative breast cancer, complete estrogen receptor antagonist OP-1250 continued to yield clinical benefits such as reductions in target tumor lesions. OP-1250, an estrogen receptor antagonist (CERAN) and selective estrogen receptor degrader (SERD), has continued to produce strong anti-tumor activity among patients with advanced and/or metastatic ER-positive, […]

Last year, Roche and Genentech paid $50 million for licensing rights to Lineage Cell Therapeutics’ OpRegen program, a cell therapy that looks to regenerate healthy versions of retinal pigment epithelial cells in patients’ eyes. Now the biotech is growing its physical presence with a new facility in the US and an expansion in Israel.

Regenerative tissue developer PolarityTE was recently granted a Regenerative Medicine Advanced Therapy (RMAT) designation from the US Food and Drug Administration for its SkinTE product. SkinTE is derived from a patient’s own skin to regenerate full-thickness, functionally polarised skin with all its layers, and including hair follicles and glands. The publicly-traded biotech company is currently enrolling patients […]